Shopping Cart
- Remove All
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $813 | Backorder | |
5 mg | $1,990 | Backorder | |
10 mg | $3,230 | Backorder |
Description | Lumasiran (ALN-G01), a siRNA product, inhibits hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes this enzyme and thereby prevents the synthesis of oxalate, the toxic metabolite directly linked to the clinical manifestations of Primary hyperoxaluria type 1 (PH1). |
In vitro | Lumasiran effectively decreased the excretion of urinary oxalate, which is responsible for the progression of kidney failure in patients with Primary Hyperoxaluria Type 1 (PH1)[1]. |
In vivo | Lumasiran sodium is a subcutaneously administered, liver-directed RNA interference (RNAi) therapeutic agent[2]. |
Alias | ALN-G01 |
Cas No. | 1834610-13-7 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.